Market Overview

UPDATE: Stifel Nicolaus Initiates Conceptus at Buy on Barrier Removal Outlook

Related CPTS
Bayer Successfully Completes Tender Offer for Conceptus
Benzinga's Top Downgrades

Stifel Nicolaus initiated coverage on Conceptus (NASDAQ: CPTS) with a Buy rating and a $26 price target.

Stifel Nicolaus noted, "We asked doctor contacts about the biggest obstacles to greater Essure adoption. The two most frequently cited answers were insurance/cost and poor compliance with hysterosalpingogram ("HSG") confirmation test. Due to the Affordable Care Act (ACA), insurance/cost issues are in the midst of being removed. The HSG is being addressed via a recently initiated clinical trial and, if successful, will be removed in 2015-2016. In the international business, France's favorable UNCAM insurance reversal should help reinvigorate European growth rates."

Conceptus closed at $22.17 on Wednesday.

Latest Ratings for CPTS

DateFirmActionFromTo
Jun 2013WunderlichTerminatesHold
May 2013Raymond JamesDowngradesOutperformMarket Perform
May 2013Roth CapitalDowngradesBuyNeutral

View More Analyst Ratings for CPTS
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (CPTS)

Around the Web, We're Loving...

Get Benzinga's Newsletters